BioTelemetry Inc (NASDAQ:BEAT) Receives Average Rating of “Buy” from Brokerages

Shares of BioTelemetry Inc (NASDAQ:BEAT) have earned a consensus recommendation of “Buy” from the ten ratings firms that are covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $76.40.

BEAT has been the subject of several analyst reports. Lake Street Capital restated a “buy” rating and set a $80.00 target price (down from $90.00) on shares of BioTelemetry in a report on Wednesday, November 6th. SunTrust Banks began coverage on BioTelemetry in a report on Tuesday, January 7th. They issued a “buy” rating and a $58.00 price objective for the company. TheStreet upgraded BioTelemetry from a “c+” rating to a “b-” rating in a report on Wednesday, November 20th. Finally, BidaskClub upgraded BioTelemetry from a “hold” rating to a “buy” rating in a report on Wednesday, January 8th.

BEAT stock traded down $0.29 during trading on Friday, hitting $53.52. 127,555 shares of the company traded hands, compared to its average volume of 235,624. The firm has a market capitalization of $1.82 billion, a PE ratio of 50.02, a P/E/G ratio of 2.48 and a beta of 1.30. BioTelemetry has a 1 year low of $37.07 and a 1 year high of $78.50. The company has a 50-day moving average of $50.55 and a 200-day moving average of $44.50. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.35 and a current ratio of 2.46.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. California State Teachers Retirement System lifted its stake in shares of BioTelemetry by 1.2% in the 3rd quarter. California State Teachers Retirement System now owns 51,713 shares of the medical research company’s stock valued at $2,106,000 after purchasing an additional 618 shares during the period. Curbstone Financial Management Corp lifted its stake in shares of BioTelemetry by 3.6% in the 4th quarter. Curbstone Financial Management Corp now owns 24,310 shares of the medical research company’s stock valued at $1,126,000 after purchasing an additional 850 shares during the period. Gabelli Funds LLC lifted its stake in shares of BioTelemetry by 62.3% in the 3rd quarter. Gabelli Funds LLC now owns 86,000 shares of the medical research company’s stock valued at $3,503,000 after purchasing an additional 33,000 shares during the period. Russell Investments Group Ltd. lifted its stake in shares of BioTelemetry by 66.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 378,631 shares of the medical research company’s stock valued at $15,421,000 after purchasing an additional 151,163 shares during the period. Finally, Rhumbline Advisers lifted its stake in shares of BioTelemetry by 1.7% in the 3rd quarter. Rhumbline Advisers now owns 102,888 shares of the medical research company’s stock valued at $4,191,000 after purchasing an additional 1,687 shares during the period. Institutional investors and hedge funds own 93.02% of the company’s stock.

BioTelemetry Company Profile

BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in Healthcare, Research, and Corporate and Other segments.

Featured Article: What is the accumulation/distribution indicator?

Analyst Recommendations for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.